These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 18097806)

  • 1. Study on the ocular pharmacokinetics of ion-activated in situ gelling ophthalmic delivery system for gatifloxacin by microdialysis.
    Liu Z; Yang XG; Li X; Pan W; Li J
    Drug Dev Ind Pharm; 2007 Dec; 33(12):1327-31. PubMed ID: 18097806
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Study of an alginate/HPMC-based in situ gelling ophthalmic delivery system for gatifloxacin.
    Liu Z; Li J; Nie S; Liu H; Ding P; Pan W
    Int J Pharm; 2006 Jun; 315(1-2):12-7. PubMed ID: 16616442
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Delivery of gatifloxacin using microemulsion as vehicle: formulation, evaluation, transcorneal permeation and aqueous humor drug determination.
    Kalam MA; Alshamsan A; Aljuffali IA; Mishra AK; Sultana Y
    Drug Deliv; 2016; 23(3):896-907. PubMed ID: 24865289
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sustained ocular delivery of brimonidine tartrate using ion activated in situ gelling system.
    Geethalakshmi A; Karki R; Jha SK; Venkatesh DP; Nikunj B
    Curr Drug Deliv; 2012 Mar; 9(2):197-204. PubMed ID: 22283647
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sustained ophthalmic delivery of ofloxacin from a pH triggered in situ gelling system.
    Srividya B; Cardoza RM; Amin PD
    J Control Release; 2001 Jun; 73(2-3):205-11. PubMed ID: 11516498
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Determination of drug concentration in aqueous humor of cataract patients administered gatifloxacin ophthalmic gel.
    Liu X; Wang NL; Wang YL; Ma C; Ma L; Gao LX; Huang YX; Xiong SH; Wang K
    Chin Med J (Engl); 2010 Aug; 123(15):2105-10. PubMed ID: 20819550
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prophylactic efficacy of ophthalmic quinolones in experimental endophthalmitis in rabbits.
    Wada T; Kozai S; Tajika T; Sakaki H; Suzuki T; Ohashi Y
    J Ocul Pharmacol Ther; 2008 Jun; 24(3):278-89. PubMed ID: 18462067
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Collagen shields as a drug delivery system for the fourth-generation fluoroquinolones.
    Kleinmann G; Larson S; Hunter B; Stevens S; Mamalis N; Olson RJ
    Ophthalmologica; 2007; 221(1):51-6. PubMed ID: 17183202
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Study of ocular pharmacokinetics of in situ gel system for S(-)-satropane evaluated by microdialysis.
    Fu J; Feng X; Yuan H; Yan L; Kuang X; Xia Z; Gao X; Yu C; Lu Y; Chen HZ
    J Pharm Biomed Anal; 2008 Nov; 48(3):840-3. PubMed ID: 18632240
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Part II: Enhancement of transcorneal delivery of gatifloxacin by solid lipid nanoparticles in comparison to commercial aqueous eye drops.
    Abul Kalam M; Sultana Y; Ali A; Aqil M; Mishra AK; Chuttani K; Aljuffali IA; Alshamsan A
    J Biomed Mater Res A; 2013 Jun; 101(6):1828-36. PubMed ID: 23184654
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ocular pharmacokinetics/pharmacodynamics of besifloxacin, moxifloxacin, and gatifloxacin following topical administration to pigmented rabbits.
    Proksch JW; Ward KW
    J Ocul Pharmacol Ther; 2010 Oct; 26(5):449-58. PubMed ID: 20874668
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fourth-generation fluoroquinolone penetration into the aqueous humor in humans.
    McCulley JP; Caudle D; Aronowicz JD; Shine WE
    Ophthalmology; 2006 Jun; 113(6):955-9. PubMed ID: 16603244
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development and evaluation of a novel in situ gel of sparfloxacin for sustained ocular drug delivery: in vitro and ex vivo characterization.
    Khan N; Aqil M; Imam SS; Ali A
    Pharm Dev Technol; 2015; 20(6):662-9. PubMed ID: 24754411
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ion-activated, Gelrite-based in situ ophthalmic gels of pefloxacin mesylate: comparison with conventional eye drops.
    Sultana Y; Aqil M; Ali A
    Drug Deliv; 2006; 13(3):215-9. PubMed ID: 16556574
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aqueous penetration and biological activity of moxifloxacin 0.5% ophthalmic solution and gatifloxacin 0.3% solution in cataract surgery patients.
    Kim DH; Stark WJ; O'Brien TP; Dick JD
    Ophthalmology; 2005 Nov; 112(11):1992-6. PubMed ID: 16183125
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Ocular pharmacokinetics and bioavailability of 0.2% ganciclovir in-situ gelling eye drops].
    Zhang JJ; Gao CF; Wang LY
    Zhonghua Yan Ke Za Zhi; 2006 Jul; 42(7):637-41. PubMed ID: 17081425
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sustained ophthalmic delivery of ofloxacin from an ion-activated in situ gelling system.
    Abraham S; Furtado S; Bharath S; Basavaraj BV; Deveswaran R; Madhavan V
    Pak J Pharm Sci; 2009 Apr; 22(2):175-9. PubMed ID: 19339228
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ocular penetration and pharmacokinetics of topical gatifloxacin 0.3% and moxifloxacin 0.5% ophthalmic solutions after keratoplasty.
    Holland EJ; Lane SS; Kim T; Raizman M; Dunn S
    Cornea; 2008 Apr; 27(3):314-9. PubMed ID: 18362660
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sustained ocular drug delivery from a temperature and pH triggered novel in situ gel system.
    Gupta H; Jain S; Mathur R; Mishra P; Mishra AK; Velpandian T
    Drug Deliv; 2007 Nov; 14(8):507-15. PubMed ID: 18027180
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Formulation and development of ophthalmic in situ gel for the treatment ocular inflammation and infection using application of quality by design concept.
    Patel N; Thakkar V; Metalia V; Baldaniya L; Gandhi T; Gohel M
    Drug Dev Ind Pharm; 2016 Sep; 42(9):1406-23. PubMed ID: 26716613
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.